Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of adjuvants in modeling the immune response

Role of adjuvants in modeling the immune response a,c a,b Darrick Carter and Steven G. Reed a b Infectious Disease Research Institute, Immune Purpose of review Design Corporation and Protein Advances Recent clinical trial results have indicated that it may be possible for vaccines to induce Incorporated, Seattle, Washington, USA protection against HIV. To build on this result, strategies should be designed to enhance Correspondence to Steven G. Reed, PhD, Infectious duration, breadth, and magnitude of antibody production. Strategic formulation of Disease Research Institute, 1124 Columbia St, Suite #400, Seattle, WA 98104, USA agonists of the innate immune system and carriers that selectively present the target Tel: +1 206 381 0883; e-mail: sreed@idri.org antigen yields a class of pharmaceuticals, named ‘adjuvants’, that greatly influence Current Opinion in HIV and AIDS 2010, immunity resulting from vaccination. As researchers begin to focus not only on creating 5:409–413 an immune response to an antigen, but also on the quality of that response, the role of adjuvants is becoming increasingly significant. This review is intended to give an overview of recent findings on how adjuvants model the immune response to antigens with a focus on the field of vaccines for HIV. Recent findings It is clear that innate and adaptive immunity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Role of adjuvants in modeling the immune response

Reed, Steven G
Current Opinion in HIV and Aids , Volume 5 (5) – Sep 1, 2010
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/role-of-adjuvants-in-modeling-the-immune-response-Mnm1A2IBL2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e32833d2cdb
pmid
20978382
Publisher site
See Article on Publisher Site

Abstract

a,c a,b Darrick Carter and Steven G. Reed a b Infectious Disease Research Institute, Immune Purpose of review Design Corporation and Protein Advances Recent clinical trial results have indicated that it may be possible for vaccines to induce Incorporated, Seattle, Washington, USA protection against HIV. To build on this result, strategies should be designed to enhance Correspondence to Steven G. Reed, PhD, Infectious duration, breadth, and magnitude of antibody production. Strategic formulation of Disease Research Institute, 1124 Columbia St, Suite #400, Seattle, WA 98104, USA agonists of the innate immune system and carriers that selectively present the target Tel: +1 206 381 0883; e-mail: sreed@idri.org antigen yields a class of pharmaceuticals, named ‘adjuvants’, that greatly influence Current Opinion in HIV and AIDS 2010, immunity resulting from vaccination. As researchers begin to focus not only on creating 5:409–413 an immune response to an antigen, but also on the quality of that response, the role of adjuvants is becoming increasingly significant. This review is intended to give an overview of recent findings on how adjuvants model the immune response to antigens with a focus on the field of vaccines for HIV. Recent findings It is clear that innate and adaptive immunity

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Sep 1, 2010

There are no references for this article.